ECSP993015A - Formulaciones de ziprasidona - Google Patents

Formulaciones de ziprasidona

Info

Publication number
ECSP993015A
ECSP993015A ECSP993015A ECSP993015A EC SP993015 A ECSP993015 A EC SP993015A EC SP993015 A ECSP993015 A EC SP993015A EC SP993015 A ECSP993015 A EC SP993015A
Authority
EC
Ecuador
Prior art keywords
crystalline ziprasidone
ziprasidone
formulations
ziprasidone formulations
schizophrenia
Prior art date
Application number
Other languages
English (en)
Inventor
Frank Robert Busch
Bijan Rasadi
Angela Carol Gatlin Hausberger
Daniel Ray Arenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP993015 priority Critical patent/ECSP993015A/es
Publication of ECSP993015A publication Critical patent/ECSP993015A/es

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones que comprenden partículas de base libre de ziprasidona cristalina o de hidrocloruro de ziprasidona cristalino, que tienen un tamaño medio de particulas inferior a 85 um y un vehículo farmacéuticamente aceptable son sustancialmente bioequivalente y se pueden usar para tratar psicósis, como esquizofrenia.
ECSP993015 1999-06-15 1999-06-15 Formulaciones de ziprasidona ECSP993015A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993015 ECSP993015A (es) 1999-06-15 1999-06-15 Formulaciones de ziprasidona

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993015 ECSP993015A (es) 1999-06-15 1999-06-15 Formulaciones de ziprasidona

Publications (1)

Publication Number Publication Date
ECSP993015A true ECSP993015A (es) 1999-10-06

Family

ID=42044004

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993015 ECSP993015A (es) 1999-06-15 1999-06-15 Formulaciones de ziprasidona

Country Status (1)

Country Link
EC (1) ECSP993015A (es)

Similar Documents

Publication Publication Date Title
MY121397A (en) Ziprasidone formulations
MY129356A (en) Electrospun pharmaceutical compositions
DK1157037T3 (da) GCSF-konjugater
GEP20043241B (en) Compounds for Treatment of Ischemia and Pharmaceutical Compositions Containing the Same
EP1100522A4 (en) ADMINISTRATION OF ACTIVE SUBSTANCES BY PULMONARY TRACT
IL153297A0 (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
EP1015008A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
PL349173A1 (en) Cosmetic compositions of high holding stability
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
AU2003228674A1 (en) Muscarinic antagonists
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
PL356100A1 (en) Lipoxin a4
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
AU1028402A (en) Stable oral formulation containing benzimidazole derivative
SE0003476D0 (sv) Compounds
AU3627200A (en) Perfume compositions and methods to mask amine malodors
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
BR0012751A (pt) Benzofuranos serotonérgicos
ECSP993015A (es) Formulaciones de ziprasidona
TNSN04077A1 (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof
ES2159260B1 (es) Nueva composicion de metanosulfonato de paroxetina
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.